Lead program
LUT014 for the Treatment of Drug-Induced Acneiform Rash
Active & Completed Studies
LUT014
Phase 2B
Acneiform lesions in certain solid tumors
RAS inhibitor- and EGFR inhibitor-induced acneiform rash in solid tumors
Planned
LUT014
Phase 2
EGFR inhibitor-induced acneiform lesions in mCRC
Double-blind, placebo-controlled, randomized, global trial
Completed
LUT014
Phase 1
Safety, tolerability and PK in healthy volunteers and patients
Safety and pharmacokinetics of LUT014 in CRC
Completed
LUT-RD
Phase 1/2
Radiation dermatitis in breast cancer patients
Safety and pharmacokinetics of LUT014 in radiation dermatitis
Completed
Caution: Investigational Drug. LUT014 is an investigational drug. It has not been approved by the U.S. Food and Drug Administration (FDA) for use by the general public. It is not approved as safe or effective, and is currently for use only in clinical trials or through approved expanded access programs. The safety and effectiveness of this product have not been fully established.
Get Involved
For Investigators & Patients
If you are an investigator interested in participating, or a patient looking for information about our trials, please reach out — we're here to help.